Daily deaths from the COVID-19 pandemic in Turkey reached an all-time peak of 243 on Thursday. Almost two million cases have been recorded in Turkey, with the nationwide average adult occupancy rate for intensive care units nearing 74%.
As the country’s daily death toll from the virus hits new highs and intensive-care beds fill up, Turkey plans to start Covid-19 vaccinations using the Chinese-made Sinovac Biotech Ltd. shots as early as next month, before it completes human trials, officials said. The government has published a change to regulations that allows the new timeframe.
The So-called phase 3 trials involving 12,500 people are yet to reach the midway mark and will only be completed in February, according to a member of the Covid-19 Science Board, a body of health professionals that advises authorities. The vaccinations will be administered based on the results from final trials in Indonesia and Brazil, as well as interim analyses in Turkey.
Turkey’s Medicine and Medical Device Agency issued the regulatory change permitting the vaccinations. In “exceptional situations” where an infectious disease threatens public health, vaccines that don’t yet have “comprehensive data on efficiency, safety and quality” may be granted an emergency-use license, according to the amendment published in the official gazette on Friday.
No comments:
Post a Comment